Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 1
2007 3
2008 3
2009 5
2010 4
2011 5
2013 5
2014 3
2017 1
2019 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Interlaboratory variability of Ki67 staining in breast cancer.
Focke CM, Bürger H, van Diest PJ, Finsterbusch K, Gläser D, Korsching E, Decker T; German Breast Screening Pathology Initiative. Focke CM, et al. Eur J Cancer. 2017 Oct;84:219-227. doi: 10.1016/j.ejca.2017.07.041. Epub 2017 Aug 19. Eur J Cancer. 2017. PMID: 28829990
The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.
Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA. Wöhrer A, et al. Among authors: reiner concin a. J Neurooncol. 2009 Dec;95(3):401-411. doi: 10.1007/s11060-009-9938-9. Epub 2009 Jun 28. J Neurooncol. 2009. PMID: 19562257
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study.
Balmativola D, Marchiò C, Maule M, Chiusa L, Annaratone L, Maletta F, Montemurro F, Kulka J, Figueiredo P, Varga Z, Liepniece-Karele I, Cserni G, Arkoumani E, Amendoeira I, Callagy G, Reiner-Concin A, Cordoba A, Bianchi S, Decker T, Gläser D, Focke C, van Diest P, Grabau D, Lips E, Wesseling J, Arisio R, Medico E, Wells C, Sapino A. Balmativola D, et al. Among authors: reiner concin a. Breast Cancer Res Treat. 2014 Dec;148(3):511-23. doi: 10.1007/s10549-014-3192-3. Epub 2014 Nov 14. Breast Cancer Res Treat. 2014. PMID: 25395316 Free PMC article.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators. Filipits M, et al. Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1. Clin Cancer Res. 2011. PMID: 21807638
Pathology role in adjuvant setting.
Reiner-Concin A. Reiner-Concin A. Cancer Treat Res. 2009;151:41-61. doi: 10.1007/978-0-387-75115-3_4. Cancer Treat Res. 2009. PMID: 19593505 Review. No abstract available.
Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.
Reiner-Concin A, Regitnig P, Dinges HP, Höfler G, Lax S, Müller-Holzner E, Obrist P, Rudas M. Reiner-Concin A, et al. Pathol Oncol Res. 2008 Sep;14(3):253-9. doi: 10.1007/s12253-008-9079-z. Epub 2008 Aug 28. Pathol Oncol Res. 2008. PMID: 18752057 Free article.
30 results